A

large private insurance company and at least five state Medicaid programs are now pushing alternative epinephrine auto-injectors instead of the branded EpiPens.

Cigna, an insurance company that serves about 15 million patients, recently changed its policy: Branded EpiPen and Adrenaclick auto-injectors will no longer be covered without a “prior authorization” from the company. Additionally, in at least three states, Medicaid recipients must obtain prior approval before buying one of the brand-name auto-injectors with insurance, and in at least five states, EpiPens are only covered with a prior authorization.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.